Market Overview

Deutsche Bank Reiterates Hold on Abbott Laboratories Following Release of MitraClip FDA Panel Documents

Share:
Related ABT
Nestle & Abbott Labs To Benefit From Chinese Demand For Nutritional Products By Selling Senior-Target Products
#PreMarket Primer: Friday, December 19: U.S. Debates A Response To Sony Hackers
Foreign Currency Headwinds Take The Spotlight In Drug Maker Earnings (Seeking Alpha)

In a report published Monday, Deutsche Bank analyst Kristen Stewart reiterated a Hold rating and $33.00 price target on Abbott Laboratories (NYSE: ABT).

In the report, Stewart noted, “The FDA has released panel documents for MitraClip, which will be evaluated by an FDA Circulatory Systems Devices Panel on March 20. The MitraClip device is a minimally invasive catheter-based device used to treat mitral regurgitation. The device received CE Mark in 2008 with sales annualizing ~$120M and has been pending FDA panel review for several years. We've had low expectations for MitraClip in the US and as such, the panel docs do not change our view on the stock. Maintain Hold.”

Abbott Laboratories closed on Friday at $34.14.

Latest Ratings for ABT

DateFirmActionFromTo
Jan 2015JefferiesMaintainsHold
Jan 2015JefferiesDowngradesBuy
Dec 2014JefferiesMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ABT)

Around the Web, We're Loving...

Get Benzinga's Newsletters